KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Total Debt (2016 - 2025)

BeOne Medicines (ONC) has disclosed Total Debt for 11 consecutive years, with $57.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt fell 94.37% to $57.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.3 million, a 94.37% decrease, with the full-year FY2025 number at $57.3 million, down 94.37% from a year prior.
  • Total Debt was $57.3 million for Q4 2025 at BeOne Medicines, down from $191.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $1.0 billion in Q4 2024 to a low of $57.3 million in Q4 2025.
  • A 5-year average of $507.6 million and a median of $488.1 million in 2023 define the central range for Total Debt.
  • Biggest YoY gain for Total Debt was 415.18% in 2025; the steepest drop was 94.37% in 2025.
  • BeOne Medicines' Total Debt stood at $629.7 million in 2021, then tumbled by 42.96% to $359.1 million in 2022, then plummeted by 44.98% to $197.6 million in 2023, then soared by 415.14% to $1.0 billion in 2024, then tumbled by 94.37% to $57.3 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Total Debt are $57.3 million (Q4 2025), $191.8 million (Q3 2025), and $954.5 million (Q2 2025).